PAYS

ANALYST NOTE: PAYS (PaySign, Inc.) Date: 2026-06-13 Analyst: StoryStocks-Native Equity Analyst

1. Structural Readiness

The setup is a confirmed coil. The breakout signal has fired, and the structure is active.

• Conservative Entry: $9.06
• Current Price: $8.98
• Extension: -0.9% vs. conservative entry.
• Setup Status: The stock is currently trading slightly below the conservative entry level of $9.06. While the breakout has fired (confirmed coil presence), the price action has not yet extended significantly above the entry threshold. This represents a partial but positive readiness state. The ATR at breakout was 4.8% (high), and current ATR is 5.0% (high), indicating the structural quality and volatility environment are within the historical sweet spot for this archetype. The setup is not "forming" in the sense of waiting for a breakout; the breakout event has occurred, but the price is currently consolidating near the entry zone.

2. The Thesis Layer

As of 2026-06-13, there is no named secular thesis attached to this name. This is a TACTICAL, setup-led name.

• Judgment Framework: Conviction must be derived strictly from the quality of the setup structure and the underlying business fundamentals reported in the evidence base. Do not invent a macro narrative. The case rests on the execution of the current business model and the technical readiness of the price action.

3. The Business

PaySign, Inc. operates as a provider of prepaid card programs, comprehensive patient affordability offerings, life science software technology solutions, digital banking services, and integrated payment processing.

• Business Model: Revenue is generated through cardholder fees, interchange fees, card program management fees, transaction claims processing fees, customer support fees, and other billable services. The company serves corporate customers, consumers, and government entities.
• Key Operational Metrics (as of Q1 2026 / FY2026 Guidance):
• Program Growth: Management stated on May 12, 2026, that they are "on track to exceed the 55 net program additions we launched in 2025." They launched 4 new programs in Q1 2026, bringing the total active programs to 135, with an expectation to exit the quarter with 147 to 150 active programs.
• Revenue & Volume: Q1 2026 revenue grew 82% year-over-year to $15.7 million, with claim volume up approximately 49% compared to Q1 2025.
• Patient Impact: The patient affordability business delivered over $540 million in financial assistance to patients in the quarter, a significant increase from $320 million in the prior year period.
• Strategic Shift: For the first time, the Pharma segment surpassed plasma to become the largest revenue contributor in the quarter.
• Market Position: The company services approximately 48% of the plasma collection centers in the United States and Puerto Rico. As of December 31, 2025, they had approximately 8.4 million cardholders participating in 670 card programs.
• Guidance: Management expects full-year 2026 revenue of $106.5 million to $110.5 million, representing 30% to 35% year-over-year growth, with gross profit margins between 60% and 62%.

4. Archetype and Conviction

• Archetype: Growth Leader / Margin Inflector.
• The company demonstrates clear top-line acceleration (82% YoY growth in Q1) and expanding margins (projected 60-62% gross margin). The shift of Pharma becoming the largest revenue contributor indicates a successful strategic pivot and margin inflection, moving away from a reliance on the plasma sector alone.
• Valuation Context: The financial spine indicates a forward consensus EPS of $0.2375 for FY1 and $0.3125 for FY2.
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro thesis).
• Evidence Quality: High. Multiple primary sources (earnings transcripts, SEC filings) confirm strong operational metrics, program expansion, and margin guidance.
• Structural Quality: High. ATR at breakout (4.8%) and current ATR (5.0%) fall within the "high" (4-6%) canonical bucket, suggesting healthy volatility without the extreme risk associated with >8% ATR.
• Setup Readiness: Positive. The coil is confirmed, though price is currently slightly below the conservative entry.
• Rerating Potential: Moderate to High. The transition to Pharma as the primary revenue driver, combined with double-digit growth and high margins, suggests a potential re-rating if the market recognizes the shift in revenue composition.

5. Invalidations, Strengtheners, and Gaps

• What Would Strengthen: Continued execution of the 30-35% revenue growth guidance; confirmation that the Pharma segment continues to outperform plasma in subsequent quarters; successful integration of the Gamma acquisition (mentioned in filings as aligning with technology and market presence).
• What Would Invalidate: A miss on the full-year revenue guidance ($106.5M-$110.5M); a contraction in gross margins below the 60% floor; a significant slowdown in new program additions (falling short of the 55 net additions target).
• Gaps in Evidence:
• Sector/Industry Classification: The evidence does not explicitly name a specific GICS sector or industry classification for the current date.
• Archetype Source: No specific archetype candidate was sourced from the provided data.
• Long-term Market Data: While Javelin data projects growth in open-loop loads and cash access, specific PaySign market share data beyond the 48% plasma figure is not detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Q1 revenue grew 82% YoY to $15.7M with claim volume up 49%; Pharma surpassed plasma as the largest revenue contributor for the first time; Management guidance projects 30-35% full-year revenue growth with 60-62% gross margins. Key risks: Tactical setup with no named secular thesis; current price is -0.9% below conservative entry; reliance on specific program addition targets to maintain growth trajectory. Rating boundary: This is rated Buy rather than Strong Buy because the setup is currently trading slightly below the conservative entry level ($8.98 vs $9.06), requiring a confirmed extension above entry to fully validate the momentum. It is rated Buy rather than Speculative due to the high-quality evidence of operational execution (82% growth, margin expansion) and the confirmed coil structure with healthy ATR metrics. Sizing hint: Position size should reflect the "high" ATR volatility and the slight discount to entry, allowing for a standard position size given the strong fundamental backing. Expected path: Management expects to exit the quarter with 147-150 active programs and maintain the trajectory of exceeding 2025's net program additions. The structural implication is continued revenue expansion as the Pharma segment scales. Expected horizon: 3 to 6 months, aligned with the full-year guidance realization and program ramp. Failure mode to watch: A miss on the full-year revenue guidance or a failure to maintain the 60% gross margin floor.